172 related articles for article (PubMed ID: 37849763)
21. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.
Wang X; Osada T; Wang Y; Yu L; Sakakura K; Katayama A; McCarthy JB; Brufsky A; Chivukula M; Khoury T; Hsu DS; Barry WT; Lyerly HK; Clay TM; Ferrone S
J Natl Cancer Inst; 2010 Oct; 102(19):1496-512. PubMed ID: 20852124
[TBL] [Abstract][Full Text] [Related]
22. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
23. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
24. Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes.
Zhao Y; Zheng Z; Khong HT; Rosenberg SA; Morgan RA
J Immunother; 2006; 29(4):398-406. PubMed ID: 16799335
[TBL] [Abstract][Full Text] [Related]
25. Chondroitin sulfate proteoglycan-4 does not protect melanoma cells during inhibition of PI3K and mTOR pathways.
Javaid S; Terai K; Dudek AZ
Anticancer Res; 2015 Mar; 35(3):1279-84. PubMed ID: 25750275
[TBL] [Abstract][Full Text] [Related]
26. Expression of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma cells is downregulated upon inhibition of BRAF.
Uranowska K; Kalic T; Valtsanidis V; Kitzwögerer M; Breiteneder H; Hafner C
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649790
[TBL] [Abstract][Full Text] [Related]
27. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.
Chinnasamy N; Wargo JA; Yu Z; Rao M; Frankel TL; Riley JP; Hong JJ; Parkhurst MR; Feldman SA; Schrump DS; Restifo NP; Robbins PF; Rosenberg SA; Morgan RA
J Immunol; 2011 Jan; 186(2):685-96. PubMed ID: 21149604
[TBL] [Abstract][Full Text] [Related]
28. A rare population of tumor antigen-specific CD4
Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
[TBL] [Abstract][Full Text] [Related]
29. Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope.
Cole DJ; Weil DP; Shamamian P; Rivoltini L; Kawakami Y; Topalian S; Jennings C; Eliyahu S; Rosenberg SA; Nishimura MI
Cancer Res; 1994 Oct; 54(20):5265-8. PubMed ID: 7522957
[TBL] [Abstract][Full Text] [Related]
30. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
Morgan RA; Dudley ME; Yu YY; Zheng Z; Robbins PF; Theoret MR; Wunderlich JR; Hughes MS; Restifo NP; Rosenberg SA
J Immunol; 2003 Sep; 171(6):3287-95. PubMed ID: 12960359
[TBL] [Abstract][Full Text] [Related]
31. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
[TBL] [Abstract][Full Text] [Related]
32. Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial.
Riccardo F; Tarone L; Camerino M; Giacobino D; Iussich S; Barutello G; Arigoni M; Conti L; Bolli E; Quaglino E; Merighi IF; Morello E; Dentini A; Ferrone S; Buracco P; Cavallo F
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580930
[TBL] [Abstract][Full Text] [Related]
33. Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4.
Chauhan J; Grandits M; Palhares LCGF; Mele S; Nakamura M; López-Abente J; Crescioli S; Laddach R; Romero-Clavijo P; Cheung A; Stavraka C; Chenoweth AM; Sow HS; Chiaruttini G; Gilbert AE; Dodev T; Koers A; Pellizzari G; Ilieva KM; Man F; Ali N; Hobbs C; Lombardi S; Lionarons DA; Gould HJ; Beavil AJ; Geh JLC; MacKenzie Ross AD; Healy C; Calonje E; Downward J; Nestle FO; Tsoka S; Josephs DH; Blower PJ; Karagiannis P; Lacy KE; Spicer J; Karagiannis SN; Bax HJ
Nat Commun; 2023 Apr; 14(1):2192. PubMed ID: 37185332
[TBL] [Abstract][Full Text] [Related]
34. Chondroitin sulfate proteoglycan 4 enhanced melanoma motility and growth requires a cysteine in the core protein transmembrane domain.
Yang J; Price MA; Wanshura LEC; He J; Yi M; Welch DR; Li G; Conner S; Sachs J; Turley EA; McCarthy JB
Melanoma Res; 2019 Aug; 29(4):365-375. PubMed ID: 31140988
[TBL] [Abstract][Full Text] [Related]
35. Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy.
Yao X; Lu YC; Parker LL; Li YF; El-Gamil M; Black MA; Xu H; Feldman SA; van der Bruggen P; Rosenberg SA; Robbins PF
J Immunother; 2016 Jun; 39(5):191-201. PubMed ID: 27163739
[TBL] [Abstract][Full Text] [Related]
36. The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma.
Simon B; Wiesinger M; März J; Wistuba-Hamprecht K; Weide B; Schuler-Thurner B; Schuler G; Dörrie J; Uslu U
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30103488
[TBL] [Abstract][Full Text] [Related]
37. Clonal analysis of in vivo activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy.
Kan-Mitchell J; Huang XQ; Steinman L; Oksenberg JR; Harel W; Parker JW; Goedegebuure PS; Darrow TL; Mitchell MS
Cancer Immunol Immunother; 1993 Jul; 37(1):15-25. PubMed ID: 8513449
[TBL] [Abstract][Full Text] [Related]
38. Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12.
Zhu S; Van den Eynde BJ; Coulie PG; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
J Immunother; 2012; 35(9):680-8. PubMed ID: 23090077
[TBL] [Abstract][Full Text] [Related]
39. Global analysis of HLA-A2 restricted MAGE-A3 tumor antigen epitopes and corresponding TCRs in non-small cell lung cancer.
Zhang B; Ren Z; Zhao J; Zhu Y; Huang B; Xiao C; Zhang Y; Deng J; Mao L; Tang L; Lan D; Gao L; Zhang H; Chen G; Luo OJ
Theranostics; 2023; 13(13):4449-4468. PubMed ID: 37649599
[No Abstract] [Full Text] [Related]
40. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]